Dupilumab: Mechanism of action, clinical, and translational science.
Saved in:
| Title: | Dupilumab: Mechanism of action, clinical, and translational science. |
|---|---|
| Authors: | McCann MR; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Kosloski MP; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Xu C; Sanofi, Bridgewater, New Jersey, USA., Davis JD; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA., Kamal MA; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. |
| Source: | Clinical and translational science [Clin Transl Sci] 2024 Aug; Vol. 17 (8), pp. e13899. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!